Posted by ABMN Staff on Apr 24th, 2024
Guggenheim reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR – Free Report) in a report released on Tuesday, Benzinga reports. Guggenheim currently has a $92.00 price objective on the stock.
A number of other...
More of this article »